Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 2 Study of Different Formulations (E1 and E2) of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)
Conditions
Interventions
Formulation E1 of L-PPDS
Formulation E2 of L-PPDS
Locations
1
United States
Menlo Park, California, United States
Start Date
August 1, 2009
Primary Completion Date
May 1, 2010
Completion Date
May 1, 2010
Last Updated
September 19, 2013
NCT04354545
NCT07298356
NCT07396441
NCT06979752
NCT07390890
NCT07145073
Lead Sponsor
Mati Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions